FDA approves Herceptin in HER2-positive metastatic gastric cancer
This article was originally published in Scrip
Executive Summary
The FDA has approved Genentech's (Roche) HER-2 targeted antibody, Herceptin (trastuzumab) in combination with chemotherapy for as a first-line treatment for HER2-positive metastatic gastric cancer. Herceptin was approved in Europe for the same indication in January 2010.